E2 ModerateModerate confidencePEM not requiredCase-ControlPeer-reviewedMachine draft
Standard · 3 min
[Association of inflammation and chronic fatigue syndrome in patients with Parkinson's disease].
Nikitina, M A, Bragina, E Yu, Ivanova, S A et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024 · DOI
Quick Summary
This study looked at severe tiredness (chronic fatigue syndrome) in people with Parkinson's disease. Researchers found that about two-thirds of Parkinson's patients experience this kind of fatigue, and it tends to occur alongside other symptoms like mood problems, memory difficulties, and pain. Blood tests showed that people with this fatigue had higher levels of inflammation markers, suggesting that inflammation may play a role in causing the tiredness.
Why It Matters
This study provides evidence that chronic fatigue in neurodegenerative disease involves inflammatory mechanisms—findings that parallel immunological hypotheses in ME/CFS. Understanding how inflammation correlates with fatigue severity across different neurological conditions may help identify shared pathways and guide therapeutic development for fatigue in both ME/CFS and Parkinson's disease.
Observed Findings
Chronic fatigue syndrome was present in 66.7% (355/533) of Parkinson's disease patients.
Patients with CFS had significantly higher serum levels of CCL5, sVCAM-1, NCAM, and slCAM-1 compared to those without CFS.
CFS co-occurred more frequently with non-motor symptoms including mood disorders, cognitive impairment, autonomic dysfunction, and pain.
Newly diagnosed, untreated PD patients with CFS showed stronger correlations between inflammatory markers and fatigue severity than treated patients.
CCL5 (rs2107538) and PAI-1 (rs2227631) genetic polymorphisms showed differences in distribution between PD patients and controls but did not influence serum protein levels or CFS development.
Inferred Conclusions
Chronic fatigue is highly prevalent in Parkinson's disease and is associated with elevated serum inflammatory markers, suggesting an inflammatory component contributes to fatigue pathogenesis.
The association between inflammatory markers and fatigue severity is strongest early in disease course before medication exposure, indicating inflammation may be a primary mechanism rather than a medication effect.
Do the identified inflammatory markers play a causal role in producing fatigue, or are they merely biomarkers of an underlying process?
What This Study Does Not Prove
This study does not establish causation—elevated inflammatory markers are associated with fatigue severity but do not prove inflammation causes the fatigue. The findings are specific to Parkinson's disease patients and may not directly apply to primary ME/CFS. Additionally, the two examined genetic polymorphisms were not associated with CFS development or protein levels, so they do not explain the fatigue-inflammation relationship.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Why do certain individuals with Parkinson's disease develop CFS while others do not, and what factors beyond these two genetic polymorphisms predict fatigue susceptibility?
Would targeting these inflammatory pathways (CCL5, VCAM-1, NCAM) therapeutically reduce fatigue severity in Parkinson's disease or ME/CFS?
How do findings in Parkinson's-associated fatigue compare mechanistically to fatigue in primary ME/CFS, and are the inflammatory signatures similar?